Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled APN01 (Alunacedase Alfa) in Healthy Volunteers
NCT05065645Phase 1Completed
- Sponsor
- APEIRON Biologics AG
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing APN01 with Placebo (2 arms). Primary endpoints: Adverse events, Supine blood pressure and 14 more. Started Oct 2021; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05065645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065645.